FDA Panel Sees Benefit in Rosuvastatin for High hsCRP

GAITHERSBURG, MD. — Findings from the JUPITER study convinced a Food and Drug Administration advisory panel that the benefits of rosuvastatin for the primary prevention of cardiovascular disease outweighed the risks in a new target population—those with high hsCRP levels.